# Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

> **NCT04256980** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT04256980
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-03
- **Primary completion:** 2021-01-29
- **Final completion:** 2023-08-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256980, "Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04256980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*